LV12201B - USE OF NITROGEN OXIDE FOR BRONHOSTENOSE TREATMENT OR PROFILE - Google Patents
USE OF NITROGEN OXIDE FOR BRONHOSTENOSE TREATMENT OR PROFILE Download PDFInfo
- Publication number
- LV12201B LV12201B LVP-98-169A LV980169A LV12201B LV 12201 B LV12201 B LV 12201B LV 980169 A LV980169 A LV 980169A LV 12201 B LV12201 B LV 12201B
- Authority
- LV
- Latvia
- Prior art keywords
- pulmonary
- ppm
- gas
- nitric oxide
- treatment
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 44
- 230000002265 prevention Effects 0.000 title claims description 13
- 206010006482 Bronchospasm Diseases 0.000 title abstract description 28
- 230000007885 bronchoconstriction Effects 0.000 title abstract description 25
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 634
- 238000000034 method Methods 0.000 claims abstract description 42
- 230000008695 pulmonary vasoconstriction Effects 0.000 claims abstract description 37
- 230000002441 reversible effect Effects 0.000 claims abstract description 23
- 239000002840 nitric oxide donor Substances 0.000 claims abstract description 18
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 239000007789 gas Substances 0.000 claims description 96
- 150000001875 compounds Chemical class 0.000 claims description 61
- 210000004072 lung Anatomy 0.000 claims description 57
- 229960003753 nitric oxide Drugs 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 40
- 208000006673 asthma Diseases 0.000 claims description 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 36
- 239000001301 oxygen Substances 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 35
- 230000002685 pulmonary effect Effects 0.000 claims description 33
- 206010021143 Hypoxia Diseases 0.000 claims description 24
- 230000001154 acute effect Effects 0.000 claims description 23
- 230000001684 chronic effect Effects 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 18
- 230000007954 hypoxia Effects 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 229940124630 bronchodilator Drugs 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 12
- 229960002460 nitroprusside Drugs 0.000 claims description 12
- 239000008246 gaseous mixture Substances 0.000 claims description 11
- 239000011261 inert gas Substances 0.000 claims description 11
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 8
- 229940048914 protamine Drugs 0.000 claims description 8
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 7
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000009423 ventilation Methods 0.000 claims description 7
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 150000001540 azides Chemical class 0.000 claims description 6
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 claims description 6
- 208000010444 Acidosis Diseases 0.000 claims description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000007950 acidosis Effects 0.000 claims description 5
- 208000026545 acidosis disease Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 206010001029 Acute pulmonary oedema Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 210000005166 vasculature Anatomy 0.000 claims description 4
- 208000003241 Fat Embolism Diseases 0.000 claims description 3
- 238000007675 cardiac surgery Methods 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 230000001960 triggered effect Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 4
- 230000001813 broncholytic effect Effects 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 239000000006 Nitroglycerin Substances 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 239000004479 aerosol dispenser Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 34
- 238000001802 infusion Methods 0.000 description 31
- 230000029058 respiratory gaseous exchange Effects 0.000 description 28
- 241000283903 Ovis aries Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 230000036593 pulmonary vascular resistance Effects 0.000 description 22
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 21
- 229960002329 methacholine Drugs 0.000 description 21
- 230000009885 systemic effect Effects 0.000 description 21
- 241000700198 Cavia Species 0.000 description 20
- 210000001147 pulmonary artery Anatomy 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 108700025647 major vault Proteins 0.000 description 15
- 238000005259 measurement Methods 0.000 description 13
- 230000004872 arterial blood pressure Effects 0.000 description 12
- 229940124549 vasodilator Drugs 0.000 description 12
- 239000003071 vasodilator agent Substances 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000000304 vasodilatating effect Effects 0.000 description 10
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000002664 inhalation therapy Methods 0.000 description 9
- 239000003380 propellant Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229960000195 terbutaline Drugs 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000283898 Ovis Species 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 230000003182 bronchodilatating effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000006199 nebulizer Substances 0.000 description 8
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 201000004193 respiratory failure Diseases 0.000 description 7
- 210000002345 respiratory system Anatomy 0.000 description 7
- 230000025033 vasoconstriction Effects 0.000 description 7
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 6
- 206010047139 Vasoconstriction Diseases 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000001146 hypoxic effect Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 230000036581 peripheral resistance Effects 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 230000024883 vasodilation Effects 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 208000000203 Hyaline Membrane Disease Diseases 0.000 description 5
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 5
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 5
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 5
- 206010001053 acute respiratory failure Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 230000006854 communication Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010061951 Methemoglobin Proteins 0.000 description 4
- 206010037423 Pulmonary oedema Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000002464 muscle smooth vascular Anatomy 0.000 description 4
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 4
- 208000005333 pulmonary edema Diseases 0.000 description 4
- 230000008704 pulmonary vasodilation Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 3
- 201000006306 Cor pulmonale Diseases 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 230000007883 bronchodilation Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 208000028831 congenital heart disease Diseases 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 208000000122 hyperventilation Diseases 0.000 description 3
- 230000000870 hyperventilation Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 208000005279 Status Asthmaticus Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000004044 bronchoconstricting agent Substances 0.000 description 2
- 230000003435 bronchoconstrictive effect Effects 0.000 description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 230000000881 depressing effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 210000004491 foramen ovale Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- -1 nitrosyl compounds Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002496 oximetry Methods 0.000 description 2
- 229960003903 oxygen Drugs 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 229940000044 respiratory system drug Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003519 ventilatory effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 102100021580 Active regulator of SIRT1 Human genes 0.000 description 1
- 229920006384 Airco Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010057621 Asphyxiating thoracic dystrophy Diseases 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- OJYGBLRPYBAHRT-OPKHMCHVSA-N Chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H](C(O)CO)OC21 OJYGBLRPYBAHRT-OPKHMCHVSA-N 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 241001503987 Clematis vitalba Species 0.000 description 1
- 206010050694 Congenital scoliosis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000032589 Diaphragmatic Congenital Hernias Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019372 Heinz bodies Diseases 0.000 description 1
- 208000035202 High altitude pulmonary edema Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021133 Hypoventilation Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000003898 Mediastinal Emphysema Diseases 0.000 description 1
- 208000034388 Mountain sickness acute Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910002089 NOx Inorganic materials 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000001184 Oligohydramnios Diseases 0.000 description 1
- 208000008883 Patent Foramen Ovale Diseases 0.000 description 1
- 206010050184 Pneumomediastinum Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010048731 Pneumopericardium Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 206010037407 Pulmonary hypoplasia Diseases 0.000 description 1
- 101150026963 RPS19BP1 gene Proteins 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- CYBACPSHBXABHX-SUYDQAKGSA-N [(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O CYBACPSHBXABHX-SUYDQAKGSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000018315 acute mountain sickness Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000008371 airway function Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 230000000682 bronchomotor Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- ZPGKBYMJBZKMAM-UHFFFAOYSA-I calcium;potassium;barium(2+);pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[K+].[Ca+2].[Ba+2] ZPGKBYMJBZKMAM-UHFFFAOYSA-I 0.000 description 1
- 231100001012 cardiac lesion Toxicity 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 201000005890 congenital diaphragmatic hernia Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000009560 cranial ultrasound Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 210000001907 heinz body Anatomy 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000008706 hypoxic vasoconstriction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 231100000037 inhalation toxicity test Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000024710 intermittent asthma Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- QWZIRCKGIJTEOQ-UHFFFAOYSA-N n,n-dimethyl-2,2-diphenylethanamine;n,n-dimethyl-3-(4-methylphenyl)-3-phenylpropan-1-amine;hydron;dichloride Chemical compound Cl.Cl.C=1C=CC=CC=1C(CN(C)C)C1=CC=CC=C1.C=1C=C(C)C=CC=1C(CCN(C)C)C1=CC=CC=C1 QWZIRCKGIJTEOQ-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009531 respiratory rate measurement Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Glass Compositions (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Exhaust Gas Treatment By Means Of Catalyst (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62286590A | 1990-12-05 | 1990-12-05 | |
| US76723491A | 1991-09-27 | 1991-09-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12201A LV12201A (lv) | 1999-01-20 |
| LV12201B true LV12201B (en) | 1999-05-20 |
Family
ID=27089304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-98-169A LV12201B (en) | 1990-12-05 | 1998-08-24 | USE OF NITROGEN OXIDE FOR BRONHOSTENOSE TREATMENT OR PROFILE |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5873359A (es) |
| EP (4) | EP1875917A3 (es) |
| JP (3) | JP2701978B2 (es) |
| AT (3) | ATE367842T2 (es) |
| AU (1) | AU657726B2 (es) |
| CA (1) | CA2097823C (es) |
| DE (9) | DE122008000012I2 (es) |
| DK (3) | DK1516639T4 (es) |
| EE (1) | EE03119B1 (es) |
| ES (3) | ES2082732T3 (es) |
| GR (3) | GR960300032T1 (es) |
| HK (3) | HK1010101A1 (es) |
| LU (3) | LU90886I2 (es) |
| LV (1) | LV12201B (es) |
| NL (3) | NL300081I2 (es) |
| SG (1) | SG47527A1 (es) |
| WO (1) | WO1992010228A1 (es) |
Families Citing this family (261)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1516639T4 (en) * | 1990-12-05 | 2015-06-29 | Gen Hospital Corp | Use of NO to treat persistent pulmonary hypertension in newborns |
| US5570683A (en) * | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
| GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
| US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| AU651882B2 (en) * | 1991-05-14 | 1994-08-04 | Visiomed Group Limited | Aerosol inhalation device |
| US6029661A (en) * | 1991-08-26 | 2000-02-29 | 3M Innovative Properties Company | Powder dispenser |
| DE4208880A1 (de) * | 1992-03-19 | 1993-09-23 | Boehringer Ingelheim Kg | Separator fuer pulverinhalatoren |
| FR2695831B1 (fr) * | 1992-09-24 | 1994-11-10 | Air Liquide | Installation et procédé de fourniture d'un mélange gazeux aux voies respiratoires d'un utilisateur. |
| US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
| WO1994023772A2 (en) * | 1993-04-06 | 1994-10-27 | Minnesota Mining And Manufacturing Company | Deagglomerators for dry powder inhalers |
| ATE204491T1 (de) * | 1993-04-17 | 2001-09-15 | Messer Griesheim Austria Ges M | Gerät zur kontrollierten zudosierung von no zur atemluft von patienten |
| DK0724723T3 (da) * | 1993-07-06 | 2000-10-23 | Kjell Alving | System til bestemmelse af NO-Nivveauer i udåndet luft og diagnostiske metoder til forstyrrelser relateret tilunormale NO-ni |
| SE501074C2 (sv) * | 1993-07-22 | 1994-11-07 | Siemens Elema Ab | Gasblandning och apparat för att tillföra gasblandningen till lungorna hos ett levande väsen |
| DE4327732C1 (de) * | 1993-08-18 | 1994-09-01 | Messer Griesheim Gmbh | NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen |
| DE4327731C1 (de) * | 1993-08-18 | 1994-11-10 | Messer Griesheim Gmbh | NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen |
| GB9320978D0 (en) * | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
| US5558083A (en) * | 1993-11-22 | 1996-09-24 | Ohmeda Inc. | Nitric oxide delivery system |
| JP3911290B2 (ja) * | 1994-05-13 | 2007-05-09 | アラダイム コーポレーション | エアゾールを含む麻酔用処方 |
| DE4419860A1 (de) * | 1994-06-07 | 1995-12-14 | Hoechst Ag | Verfahren und Filter zur Herstellung von NO¶2¶-freiem Stickstoffmonoxid mit schwefelhaltigen Polymeren |
| US5615669A (en) * | 1994-07-22 | 1997-04-01 | Siemens Elema Ab | Gas mixture and device for delivering the gas mixture to the lungs of a respiratory subject |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| US5665077A (en) * | 1995-04-24 | 1997-09-09 | Nitrosci Pharmaceuticals Llc | Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis |
| SE506208C2 (sv) | 1995-07-05 | 1997-11-24 | Aerocrine Systems Kb | Anordning för uppsamling av gas från de övre luftvägarna och leverans av denna gas till inandningsluften i en respirator |
| RU2072241C1 (ru) * | 1995-09-20 | 1997-01-27 | Панина Елена Владимировна | Способ формирования дыхательной газовой смеси и аппарат для его осуществления |
| DE69618133T2 (de) * | 1995-10-13 | 2002-07-11 | Siemens-Elema Ab, Solna | Trachealtubus und Vorrichtung für Beatmungssysteme |
| EP0855912B1 (fr) * | 1995-10-20 | 2001-12-05 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Composition a base de monoxyde d'azote en tant que medicament |
| AU7529796A (en) * | 1995-11-13 | 1997-06-05 | Brigham And Women's Hospital | S-nitroso-hemoglobin and therapeutic uses thereof |
| US5699790A (en) * | 1996-03-21 | 1997-12-23 | Ohmeda Inc. | System for predicting NO2 concentrations |
| ATE331505T1 (de) * | 1996-04-05 | 2006-07-15 | Gen Hospital Corp | Behandlung einer hämoglobinstörung |
| US5765548A (en) * | 1996-05-07 | 1998-06-16 | Perry; Bryan J. | Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine |
| US5811437A (en) * | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
| US5732694A (en) * | 1996-12-13 | 1998-03-31 | Ohmeda Inc. | System for correcting NO2 monitor |
| CA2206477A1 (en) | 1996-07-10 | 1998-01-10 | Ohmeda Inc. | System for correcting no2 monitor |
| US6720309B1 (en) * | 1996-07-17 | 2004-04-13 | Leuven Research And Development, V.Z.W. | Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene |
| CA2260771A1 (en) * | 1996-07-17 | 1998-01-22 | The General Hospital Corporation | Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene |
| JP3880103B2 (ja) * | 1996-07-18 | 2007-02-14 | 住友精化株式会社 | 医療用一酸化窒素混合ガスおよびその製造方法 |
| SE506778C2 (sv) * | 1996-08-12 | 1998-02-09 | Siemens Elema Ab | Förfarande vid blandning av gaser och en anordning för blandning av gaser |
| WO1998007020A1 (en) * | 1996-08-13 | 1998-02-19 | University Of Massachusetts | Nitric oxide sensor |
| DE19734279A1 (de) * | 1997-08-07 | 1999-02-11 | Messer Griesheim Gmbh | Wasserstoffhaltiges Medikament |
| US5732693A (en) | 1996-10-02 | 1998-03-31 | Ohmeda Inc. | Pause control of nitric oxide therapy |
| JP2001517108A (ja) | 1997-01-17 | 2001-10-02 | メッサー オーストリア ゲゼルシャフト ミット ベシュレンクテル ハフツング | 制御されるガス供給システム |
| US6027713A (en) * | 1997-03-06 | 2000-02-22 | Meri Charmyne Russell | Composition and method for the treatment of exercise induced pulmonary hemorrhage |
| SE9700940D0 (sv) * | 1997-03-14 | 1997-03-14 | Astra Ab | Powder inhaler IV |
| CA2225013C (en) | 1997-04-04 | 2006-06-06 | Institut Du N.O. Inc. | Injection system for delivery of a gaseous substance |
| WO1998046277A2 (en) * | 1997-04-16 | 1998-10-22 | Ohmeda, Inc. | Humidity compensation for fuel cell zeroing in respiratory gas measurement |
| US5918596A (en) * | 1997-04-22 | 1999-07-06 | Instrumentarium Corp. | Special gas dose delivery apparatus for respiration equipment |
| FR2762992B1 (fr) * | 1997-05-07 | 2000-08-25 | Air Liquide | Transporteurs de no a base de complexes polyazamacrocycles de fer et de cobalt |
| US6125846A (en) * | 1997-05-16 | 2000-10-03 | Datex-Ohmeda, Inc. | Purge system for nitric oxide administration apparatus |
| US6656452B1 (en) | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
| US6109260A (en) * | 1998-02-18 | 2000-08-29 | Datex-Ohmeda, Inc. | Nitric oxide administration device with timed pulse |
| US6142147A (en) * | 1998-03-31 | 2000-11-07 | The General Hospital Corporation | Nasal delivery system for inhaled nitric oxide |
| CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
| US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
| JP3641151B2 (ja) * | 1999-02-04 | 2005-04-20 | 帝人株式会社 | 治療用ガス投入用呼吸マスク |
| US9486429B2 (en) * | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
| US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
| FR2795644B1 (fr) * | 1999-07-02 | 2004-07-30 | Air Liquide Sante Int | Utilisations therapeutiques d'un melange helium/oxygene, en particulier dans le traitement de l'asthme |
| CA2375679C (en) * | 1999-07-12 | 2008-09-23 | Capnia, Incorporated | Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| CA2680378C (en) * | 1999-08-02 | 2013-09-24 | Duke University | Method for determining physiological effects of hemoglobin |
| US7045152B2 (en) * | 1999-09-08 | 2006-05-16 | Duke University | Treating pulmonary disorders with gaseous agent causing repletion of GSNO |
| US6314956B1 (en) * | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
| US6694969B1 (en) | 1999-09-22 | 2004-02-24 | Instrumentarium Corp. | Method to improve oxygenation in subjects suffering impaired oxygenation |
| DE60027403T2 (de) | 1999-09-22 | 2006-10-19 | Instrumentarium Corp. | Verbesserung der Sauerstoffversorgung in Lebewesen mit gestörter Sauerstoffversorgung |
| US6612306B1 (en) | 1999-10-13 | 2003-09-02 | Healthetech, Inc. | Respiratory nitric oxide meter |
| CA2388979C (en) | 1999-10-29 | 2010-09-14 | Orion Corporation | Treatment or prevention of hypotension and shock with use of an imidazole derivative |
| SE9903985D0 (sv) * | 1999-11-03 | 1999-11-03 | Aga Ab | Use of nitric oxide |
| US20070039615A1 (en) * | 1999-11-08 | 2007-02-22 | Capnia, Incorporated | Methods and apparatus for treating rhinitis |
| US6959708B1 (en) * | 1999-11-08 | 2005-11-01 | Capnia, Incorporated | Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments |
| US20060172017A1 (en) | 1999-11-08 | 2006-08-03 | Capnia, Incorporated | Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces |
| US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
| US6581599B1 (en) * | 1999-11-24 | 2003-06-24 | Sensormedics Corporation | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients |
| US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
| JP2003531123A (ja) * | 2000-04-13 | 2003-10-21 | イノバータ・バイオミッド・リミテッド | 医薬品 |
| US6601580B1 (en) * | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
| US6951215B1 (en) * | 2000-07-14 | 2005-10-04 | Tufts University | Drug delivery device for animals |
| AU8484901A (en) * | 2000-08-11 | 2002-02-25 | David R Whitlock | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
| WO2002026112A2 (en) | 2000-09-29 | 2002-04-04 | Healthetech, Inc. | Indirect calorimetry system |
| US6668828B1 (en) | 2000-10-16 | 2003-12-30 | Pulmonox Technologies Corporations | System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient |
| SE0004229D0 (sv) * | 2000-11-17 | 2000-11-17 | Aga Ab | Inhalation of nitric oxide |
| US7335181B2 (en) * | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
| US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
| US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| AUPR315401A0 (en) * | 2001-02-16 | 2001-03-15 | Resmed Limited | An apparatus for supplying clean breathable gas |
| WO2002087673A1 (de) * | 2001-04-25 | 2002-11-07 | Messer Austria Gmbh | Aerosoldosiergerät |
| US6749834B2 (en) * | 2001-06-19 | 2004-06-15 | World Precision Instruments, Inc. | Methods and apparatus for therapeutic treatment of respiratory, cardiac and other pathologies |
| EP2565157B1 (en) | 2001-09-05 | 2017-10-04 | Geno LLC | Nitric oxide generation |
| US6575918B2 (en) | 2001-09-27 | 2003-06-10 | Charlotte-Mecklenburg Hospital | Non-invasive device and method for the diagnosis of pulmonary vascular occlusions |
| US20030070674A1 (en) * | 2001-10-12 | 2003-04-17 | Bryan Perry | Use of aerosolized compounds in the treatment of exercise induced pulmonary hemorrhage in an equine |
| GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
| US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
| US6472390B1 (en) * | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
| US20050244382A9 (en) * | 2002-01-11 | 2005-11-03 | Whitlock David R | Compositions including ammonia oxidizing bacteria and methods of using same |
| US20030170223A1 (en) * | 2002-02-01 | 2003-09-11 | Board Of Trustees Of Michigan State University | Pulmonary vasodilator surfactant compositions and method of use |
| US7086397B2 (en) * | 2002-02-16 | 2006-08-08 | Graham Lindley Spruiell | Patient usable emergency medical kit |
| WO2003102575A1 (en) * | 2002-05-29 | 2003-12-11 | Duke University | Measuring nitric oxide in blood gases and treatments based thereon |
| MXPA04012863A (es) * | 2002-06-21 | 2005-03-31 | Univ Pittsburgh | Uso farmaceutico de oxido nitrico, heme oxigenasa-1 y productos de degradacion de heme. |
| EP3335752A1 (en) * | 2002-06-28 | 2018-06-20 | The Research Foundation of the State University of New York | Therapeutic agent delivery device and method |
| US7337776B2 (en) * | 2002-08-20 | 2008-03-04 | Aga Ab | Methods for easing pain and anxiety from atrial or ventricular defibrillation |
| US7681572B2 (en) * | 2002-08-20 | 2010-03-23 | Aga Ab | Method and devices for administration of therapeutic gases |
| AU2003259897B2 (en) * | 2002-08-20 | 2008-04-03 | Aga Ab | Methods and devices for administration of therapeutic gases |
| US8001962B2 (en) * | 2002-08-23 | 2011-08-23 | Sheiman Ultrasonic Research Foundation Pty Ltd. | Nebulizing and drug delivery device |
| US7828739B2 (en) * | 2002-08-27 | 2010-11-09 | Precision Pulsus, Inc. | Apnea detection system |
| US6869402B2 (en) * | 2002-08-27 | 2005-03-22 | Precision Pulsus, Inc. | Method and apparatus for measuring pulsus paradoxus |
| US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
| WO2004032964A1 (ja) * | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | アレルギー性疾患治療剤 |
| US9138707B2 (en) | 2002-12-10 | 2015-09-22 | Sy Kimball | Portable, nitric oxide generator |
| CA2413834A1 (en) | 2002-12-10 | 2004-06-10 | 1017975 Alberta Limited | Nitric oxide gas generator |
| SE0300971D0 (sv) * | 2003-04-03 | 2003-04-03 | Aga Ab | Nitric oxide in treatment of inflammation |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| JP5564158B2 (ja) | 2003-07-09 | 2014-07-30 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 亜硝酸塩によって特定の心臓血管状態を処置する方法 |
| BRPI0414813A (pt) * | 2003-09-26 | 2006-11-14 | David R Whitlock | método para o uso de bactéria que oxidam a amÈnia |
| US7552731B2 (en) * | 2003-11-14 | 2009-06-30 | Remcore, Inc. | Remote control gas regulation system |
| WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
| US20050191245A1 (en) * | 2004-02-27 | 2005-09-01 | Adams Christopher P. | Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders |
| JP2007526316A (ja) * | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
| US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| WO2005089738A2 (en) * | 2004-03-17 | 2005-09-29 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
| JP2007537267A (ja) * | 2004-05-11 | 2007-12-20 | センサーメディックス・コーポレイション | 一酸化窒素ガスの間欠的投与 |
| US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
| US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US7618594B2 (en) * | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| EP1789119B1 (en) * | 2004-08-18 | 2017-10-18 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
| US7814901B2 (en) * | 2005-03-09 | 2010-10-19 | Ric Investments, Llc | Nebulizing drug delivery device with increased flow rate |
| US7721729B2 (en) * | 2005-03-09 | 2010-05-25 | Ric Investments, Llc | Nebulizing drug delivery device for ventilator |
| US7631643B2 (en) | 2005-03-09 | 2009-12-15 | Ric Investments, Llc | Nebulizing drug delivery device with interlock detection and temperature protection |
| US8056557B2 (en) * | 2005-03-09 | 2011-11-15 | Ric Investments, Llc | Nebulizing drug delivery device with barrier |
| WO2006125123A2 (en) * | 2005-05-19 | 2006-11-23 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
| EP2021131B1 (en) * | 2005-05-23 | 2011-07-13 | Biosonic Australia Pty. Ltd. | Apparatus for atomisation and liquid filtration |
| US7523752B2 (en) | 2005-09-21 | 2009-04-28 | Ino Therapeutics, Llc | System and method of administering a pharmaceutical gas to a patient |
| US8893717B2 (en) | 2005-09-21 | 2014-11-25 | Ino Therapeutics Llc | Systems and methods of administering a pharmaceutical gas to a patient |
| US7566308B2 (en) * | 2005-10-13 | 2009-07-28 | Cardiac Pacemakers, Inc. | Method and apparatus for pulmonary artery pressure signal isolation |
| US20070116785A1 (en) * | 2005-11-18 | 2007-05-24 | Miller Christopher C | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
| EP1962869B1 (en) * | 2005-12-21 | 2013-03-20 | SolAeroMed Inc. | Treatment of respiratory diseases |
| US8790715B2 (en) | 2006-02-16 | 2014-07-29 | Ino Therapeutics Llc | Method and apparatus for generating nitric oxide for medical use |
| US20100313883A1 (en) * | 2006-04-20 | 2010-12-16 | Koninklijke Philips Electronics N.V. | Ultrasonic bebulilzer with metal coated ultrasonic genrator |
| US9259535B2 (en) | 2006-06-22 | 2016-02-16 | Excelsior Medical Corporation | Antiseptic cap equipped syringe |
| US11229746B2 (en) | 2006-06-22 | 2022-01-25 | Excelsior Medical Corporation | Antiseptic cap |
| EP1903003B1 (de) | 2006-07-05 | 2017-07-05 | BSN medical GmbH | Verfahren zur photolytischen Erzeugung von Stickstoffmonoxid |
| US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
| US8887721B2 (en) * | 2006-11-07 | 2014-11-18 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
| WO2008079993A2 (en) * | 2006-12-22 | 2008-07-03 | Ikaria, Inc. | Combinations of nitric oxide and sulfide and methods of use and manufacture thereof |
| US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
| US8176915B2 (en) * | 2007-03-15 | 2012-05-15 | Koninklijke Philips Electronics N.V. | End-tidal gas estimation system and method |
| US8166971B2 (en) * | 2007-03-15 | 2012-05-01 | Ric Investments, Llc | End-tidal gas estimation system and method |
| CA2681308C (en) | 2007-03-23 | 2015-11-24 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| WO2009048521A1 (en) * | 2007-10-11 | 2009-04-16 | Duke University | Potentiating the effect of compound comprising nitric oxide |
| EP2534957B1 (en) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Delivering aerosolizable products |
| WO2009086470A2 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
| EP2247381B1 (en) | 2008-01-28 | 2016-11-30 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| US9649467B2 (en) | 2008-01-31 | 2017-05-16 | Syk Technologies, Llc | Nitric oxide reactor and distributor apparatus and method |
| DK2247297T3 (en) * | 2008-01-31 | 2019-03-11 | Univ Vanderbilt | THERAPEUTIC TREATMENT OF LUNG CONDITIONS |
| JP5623916B2 (ja) | 2008-01-31 | 2014-11-12 | バンダービルト・ユニバーシティＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物 |
| US8720436B2 (en) * | 2008-01-31 | 2014-05-13 | Genosys, Inc. | Nitric oxide gel apparatus and method |
| US8434475B2 (en) | 2008-01-31 | 2013-05-07 | Genosys, Inc. | Nitric oxide reactor and distributor apparatus and method |
| US8501090B2 (en) * | 2008-03-24 | 2013-08-06 | Christian S. Minton | Anti-microbial gas apparatus and method |
| US20100040703A1 (en) * | 2008-08-13 | 2010-02-18 | Chris Miller | Use of nitric oxide |
| US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
| US10780241B2 (en) * | 2008-08-21 | 2020-09-22 | Vero Biotech LLC | Devices and methods for minimizing and treating high-altitude sickness |
| US10960168B2 (en) | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
| GB2463883A (en) * | 2008-09-25 | 2010-03-31 | Pharma Patents Ltd | A pharmaceutical composition comprising an A-SMase inhibitor and an NO-donor |
| US9078992B2 (en) | 2008-10-27 | 2015-07-14 | Pursuit Vascular, Inc. | Medical device for applying antimicrobial to proximal end of catheter |
| AU2010248776B2 (en) * | 2009-05-15 | 2013-06-06 | Baudax Bio, Inc. | Sublingual dexmedetomidine compositions and methods of use thereof |
| KR101567125B1 (ko) | 2009-05-27 | 2015-11-06 | 이노 테라퓨틱스 엘엘씨 | 인덱싱된 밸브와 압축 캐니스터 조립체를 칼라에 결합하고 플런저 조립체로 선형 작동시켜 약물 전달 조절용 장치와 유체 소통상태가 되게 하는 방법 및 장치 |
| CA2763804C (en) | 2009-06-22 | 2018-02-06 | Geno Llc | Nitric oxide therapies |
| JP2011010865A (ja) | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
| WO2011063335A1 (en) * | 2009-11-20 | 2011-05-26 | Geno Llc | Nitric oxide delivery system |
| JP5911475B2 (ja) | 2010-04-26 | 2016-04-27 | ゲノ エルエルシー | 超高純度一酸化窒素（ｎｏ）の送達 |
| DE102010016699A1 (de) | 2010-04-29 | 2011-11-03 | Maquet Gmbh & Co. Kg | Verfahren und Vorrichtung zur Applikation mindestens eines medizinischen Gases an einen mit Hilfe eines Beatmungsgeräts beatmeten Patienten |
| US8685467B2 (en) | 2010-08-03 | 2014-04-01 | J. W. Randolph Miller | Nitric oxide generation, dilution, and topical application apparatus and method |
| ES2711974T3 (es) * | 2010-09-10 | 2019-05-08 | Ino Therapeutics Llc | Composiciones, métodos y artículos que se refieren al óxido nítrico farmacéutico y los sistemas controlados de administración al paciente del mismo |
| WO2012037665A1 (en) | 2010-09-24 | 2012-03-29 | Oral Delivery Technology Ltd. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
| US9776161B2 (en) | 2010-12-03 | 2017-10-03 | Koninklijke Philips N.V. | Method and arrangement for generating nitric oxide |
| AU2011328891B2 (en) | 2011-01-06 | 2014-11-20 | Mallinckrodt Hospital Products IP Limited | Gas delivery device and system |
| US10445846B2 (en) * | 2011-04-14 | 2019-10-15 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
| US9626650B2 (en) * | 2011-04-14 | 2017-04-18 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
| US10166381B2 (en) | 2011-05-23 | 2019-01-01 | Excelsior Medical Corporation | Antiseptic cap |
| FR2976260B1 (fr) † | 2011-06-09 | 2013-07-05 | Air Liquide | Procede de conditionnement de melanges no/n2 avec etapes de purge et rincage gazeux prealable |
| WO2013009998A2 (en) | 2011-07-12 | 2013-01-17 | Pursuit Vascular, Inc. | Device for delivery of antimicrobial agent into trans-dermal catheter |
| CA3003708C (en) | 2011-10-03 | 2019-01-15 | NitricGen, Inc. | Apparatus and method for generating nitric oxide in controlled and accurate amounts |
| US9572833B2 (en) | 2011-11-07 | 2017-02-21 | The General Hospital Corporation | Treatment of red blood cells |
| SG11201403094TA (en) | 2011-12-11 | 2014-10-30 | Recro Pharma Inc | Intranasal dexmedetomidine compositions and methods of use thereof |
| CN104411317A (zh) | 2012-03-15 | 2015-03-11 | Ino治疗有限责任公司 | 用于施用高浓度一氧化碳的方法 |
| FR2990858B1 (fr) * | 2012-05-24 | 2015-04-03 | Air Liquide Sante Int | Melange gazeux no/azote a teneur elevee en no pour traiter les detresses respiratoires hypoxemiantes severes |
| FR2991026B1 (fr) | 2012-05-24 | 2014-07-04 | Air Liquide Sante Int | Conditionnement a haute pression d'un melange gazeux no/azote |
| FR2991025B1 (fr) | 2012-05-24 | 2014-07-04 | Air Liquide Sante Int | Conditionnement d'un melange gazeux no/azote a haute concentration en no |
| KR102357044B1 (ko) | 2012-12-04 | 2022-02-08 | 말린크로트 파마슈티칼스 아일랜드 리미티드 | 일산화질소 전달 동안 투약량의 희석을 최소화하기 위한 캐뉼라 |
| US9795756B2 (en) | 2012-12-04 | 2017-10-24 | Mallinckrodt Hospital Products IP Limited | Cannula for minimizing dilution of dosing during nitric oxide delivery |
| EP2961479A4 (en) | 2013-02-28 | 2017-07-05 | Aires Pharmaceuticals, Inc. | Inorganic nitrite to improve cardiopulmonary hemodynamics |
| MX370385B (es) | 2013-03-15 | 2019-12-11 | Massachusetts Gen Hospital | Sintesis inspiratoria de oxido nitrico. |
| BR112015022468B1 (pt) | 2013-03-15 | 2022-11-01 | The General Hospital Corporation | Aparelho e método para síntese do gás óxido nítrico para inalação |
| US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
| US20140373836A1 (en) | 2013-06-25 | 2014-12-25 | Ino Therapeutics Llc | Methods of Reducing the Risk of Mortality Associated With a Medical Treatment |
| US9522247B2 (en) | 2013-06-28 | 2016-12-20 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Method of treating a patient having pulmonary hypertension by long term NO therapy |
| US9566407B2 (en) | 2013-06-28 | 2017-02-14 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Nasal cannula assembly with flow control passage communicating with a deformable reservoir |
| US9486600B2 (en) | 2013-06-28 | 2016-11-08 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Nasal cannula assembly with inhalation valves communicating with a deformable reservoir |
| US9517318B2 (en) | 2013-06-28 | 2016-12-13 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Method of delivering medical gases via a nasal cannula assembly with flow control passage communicating with a deformable reservoir |
| US9492626B2 (en) | 2013-06-28 | 2016-11-15 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Breathing assistance assemblies suitable for long term no therapy |
| US9522248B2 (en) | 2013-06-28 | 2016-12-20 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Breathing assistance apparatus for delivery of nitric oxide to a patient by means of a nasal cannula assembly with flow control passage |
| US10183039B2 (en) | 2013-07-15 | 2019-01-22 | Vanderbilt University | Methods for the production of collagen IV |
| FR3015000B1 (fr) | 2013-12-12 | 2016-05-27 | Air Liquide Sante (International) | Systeme de stockage et de distribution de melanges no/azote |
| WO2015120389A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| PT3104854T (pt) | 2014-02-10 | 2020-06-26 | Respivant Sciences Gmbh | Estabilizadores de mastócitos para tratamento de doença pulmonar |
| WO2015157524A1 (en) * | 2014-04-09 | 2015-10-15 | 12th Man Technologies, Inc. | Systems and methods for high concentration nitric oxide delivery |
| EP4219679A3 (en) | 2014-04-15 | 2023-08-09 | Aobiome LLC | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
| US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
| EP2937089A1 (en) | 2014-04-23 | 2015-10-28 | Linde AG | Device for the treatment of, treatment of complications arising from, and/or prevention of respiratory disorders |
| AU2015252808B2 (en) | 2014-05-02 | 2019-02-21 | Excelsior Medical Corporation | Strip package for antiseptic cap |
| WO2016064928A1 (en) | 2014-10-20 | 2016-04-28 | Geno Llc | Nitrogen dioxide storage cassette |
| BR112017007841B1 (pt) | 2014-10-20 | 2022-11-08 | The General Hospital Corporation | Aparelho para gerar óxido nítrico |
| CN111603643B (zh) | 2015-04-02 | 2023-05-23 | 希尔－罗姆服务私人有限公司 | 呼吸装置的压力控制 |
| WO2016182822A1 (en) | 2015-05-08 | 2016-11-17 | Icu Medical, Inc. | Medical connectors configured to receive emitters of therapeutic agents |
| WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP3347096A4 (en) * | 2015-09-09 | 2019-05-15 | Advanced Inhalation Therapies (AIT) Ltd. | STICK OXIDE INHALATION THERAPY FOR SMALL CHILDREN WITH BRONCHIOLITIS |
| US9744190B2 (en) | 2016-01-15 | 2017-08-29 | Thomas Tait | Continuous gas generator |
| FI3407900T3 (fi) | 2016-01-27 | 2024-03-21 | Syk Tech Llc | Laitteisto typpioksidin paikalliseksi levittämiseksi ja menetelmiä |
| EP3413899A4 (en) * | 2016-02-12 | 2019-10-02 | Mallinckrodt Hospital Products IP Limited | USE AND MONITORING OF INHALED STAIN OXIDE WITH LEFT-VENTRICULAR SUPPORT DEVICES |
| RU2768488C2 (ru) | 2016-03-25 | 2022-03-24 | Дзе Дженерал Хоспитал Корпорейшн | Системы доставки и способы для электрического плазменного синтеза оксида азота |
| EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| SI3525865T1 (sl) | 2016-10-14 | 2023-01-31 | Icu Medical, Inc. | Razkuževalni pokrovčki za medicinske konektorje |
| MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
| EP4163253A1 (en) | 2017-02-27 | 2023-04-12 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
| EP3585727B1 (en) | 2017-02-27 | 2022-03-16 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
| US10239038B2 (en) | 2017-03-31 | 2019-03-26 | The General Hospital Corporation | Systems and methods for a cooled nitric oxide generator |
| WO2018204206A2 (en) | 2017-05-01 | 2018-11-08 | Icu Medical, Inc. | Medical fluid connectors and methods for providing additives in medical fluid lines |
| AU2018358349A1 (en) * | 2017-11-02 | 2020-05-28 | Beyond Air, Inc. | Inhalation of nitric oxide |
| JP6618976B2 (ja) * | 2017-11-14 | 2019-12-11 | イノ セラピューティクス エルエルシー | 指標付弁と襟部を有する加圧容器組立体を係合するため、かつ薬物送達を調整するための装置と流体連通したプランジャ組立体により直線的に作動させるための装置および方法 |
| US20210386944A1 (en) * | 2018-10-12 | 2021-12-16 | Sanotize Research Development Corp. | Gas-evolving compositions and container and delivery systems |
| US11541221B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Tubing set with antimicrobial properties |
| US11541220B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Needleless connector with antimicrobial properties |
| US11400195B2 (en) | 2018-11-07 | 2022-08-02 | Icu Medical, Inc. | Peritoneal dialysis transfer set with antimicrobial properties |
| US11517732B2 (en) | 2018-11-07 | 2022-12-06 | Icu Medical, Inc. | Syringe with antimicrobial properties |
| US11534595B2 (en) | 2018-11-07 | 2022-12-27 | Icu Medical, Inc. | Device for delivering an antimicrobial composition into an infusion device |
| JP2022513096A (ja) | 2018-11-21 | 2022-02-07 | アイシーユー・メディカル・インコーポレーテッド | リング及びインサートを有するキャップを備える抗菌装置 |
| WO2020213398A1 (ja) * | 2019-04-19 | 2020-10-22 | 国立研究開発法人物質・材料研究機構 | 窒素系ガス徐放剤及びこれで構成された窒素系ガス徐放体、並びに該徐放体を用いた窒素系ガスの徐放方法、呼吸器具、包装体及び徐放装置 |
| CN114269685A (zh) | 2019-05-15 | 2022-04-01 | 第三极股份有限公司 | 用于一氧化氮生成的电极 |
| EP3969416A4 (en) | 2019-05-15 | 2023-11-01 | Third Pole, Inc. | SYSTEMS AND METHODS FOR GENERATING NITRIC OXIDE |
| FR3103110B1 (fr) | 2019-11-15 | 2021-10-08 | Air Liquide | Dispositif de fourniture de gaz thérapeutique, en particulier de NO ou de N2O, à un patient |
| WO2021105900A1 (en) | 2019-11-25 | 2021-06-03 | Beyond Air, Inc. | System and method for delivery of gas to a tissue |
| US11691879B2 (en) | 2020-01-11 | 2023-07-04 | Third Pole, Inc. | Systems and methods for nitric oxide generation with humidity control |
| WO2021258025A1 (en) | 2020-06-18 | 2021-12-23 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
| EP4433066A1 (en) * | 2020-11-12 | 2024-09-25 | Thermolife International, LLC | Methods of increasing blood oxygen saturation |
| US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
| AU2021396147A1 (en) | 2020-12-07 | 2023-06-29 | Icu Medical, Inc. | Peritoneal dialysis caps, systems and methods |
| US11975139B2 (en) | 2021-09-23 | 2024-05-07 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
| FR3127408B1 (fr) | 2021-09-29 | 2024-05-10 | Inosystems | Chariot hospitalier de transport de bouteille de gaz, notamment de NO médical |
| FR3137841B1 (fr) | 2022-07-18 | 2024-06-14 | Inosystems | Dispositif de délivrance de NO avec système de dosage d’urgence |
| FR3131538A1 (fr) | 2022-01-05 | 2023-07-07 | Inosystems | Dispositif de délivrance de NO avec système de dosage d’urgence |
| EP4209243B1 (fr) | 2022-01-05 | 2024-08-14 | Inosystems | Dispositif de délivrance de no avec système de dosage d'urgence |
| FR3132025A1 (fr) | 2022-01-24 | 2023-07-28 | Inosystems | Cartouche de stockage d’un mélange NO/azote et installation de fourniture de gaz associée |
| FR3133317B1 (fr) | 2022-03-09 | 2024-03-01 | Inosystems | Appareil de délivrance de NO avec système de ventilation manuelle |
| FR3133316B1 (fr) | 2022-03-09 | 2024-04-12 | Inosystems | Dispositif de délivrance de NO avec circuit de secours |
| FR3133315B1 (fr) | 2022-03-09 | 2024-03-22 | Inosystems | Appareil de délivrance de NO à deux sorties de gaz |
| FR3133318B1 (fr) | 2022-03-09 | 2024-03-22 | Inosystems | Dispositif de délivrance de NO avec circuit de secours à débit contrôlé |
| FR3136986B1 (fr) | 2022-06-24 | 2024-06-14 | Inosystems | Affichage de la dose de NO par un dispositif de fourniture de NO en phase de pause |
| FR3138773B1 (fr) | 2022-08-11 | 2024-08-02 | Inosystems | Installation de fourniture de gaz comprenant un ventilateur médical et un dispositif de délivrance de NO avec un système de dosage d’urgence |
| FR3145873A1 (fr) | 2023-02-20 | 2024-08-23 | Inosystems | Appareil de fourniture de gaz, tel du NO, à un patient avec comptage du temps total de traitement effectif |
| FR3146810A1 (fr) | 2023-03-21 | 2024-09-27 | Inosystems | Dispositif de calibration des capteurs d’un appareil de délivrance de NO |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3367332A (en) * | 1965-08-27 | 1968-02-06 | Gen Electric | Product and process for establishing a sterile area of skin |
| US3785377A (en) * | 1970-11-12 | 1974-01-15 | S Jorgensen | Plant, preferably for anaesthesia |
| US3745991A (en) * | 1971-02-22 | 1973-07-17 | Champion Spark Plug Co | Environmental contamination control device |
| US4010897A (en) * | 1976-03-31 | 1977-03-08 | Charles F. Kettering Foundation | Method and apparatus for home production and application of nitrogen fertilizer |
| IL57239A (en) * | 1979-05-08 | 1982-04-30 | Alamaro Moshe | Production of nitric oxides |
| US4297123A (en) * | 1980-02-07 | 1981-10-27 | Wyse Harold G | Method and apparatus for producing a nitrate fertilizer |
| US4336798A (en) * | 1980-10-06 | 1982-06-29 | Anthony V. Beran | Medical corrugated respiratory tube |
| SE438261B (sv) * | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4484577A (en) * | 1981-07-23 | 1984-11-27 | Key Pharmaceuticals, Inc. | Drug delivery method and inhalation device therefor |
| US4534343A (en) * | 1984-01-27 | 1985-08-13 | Trutek Research, Inc. | Metered dose inhaler |
| US4592348A (en) * | 1984-12-17 | 1986-06-03 | Waters Iv William C | Aerosol inhaler |
| US4675174A (en) * | 1985-08-16 | 1987-06-23 | Alza Corporation | Veterinary dispenser delivering beneficial agent by gas power generated in situ |
| US4852561A (en) * | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
| US4877589A (en) * | 1988-09-19 | 1989-10-31 | Hare Louis R O | Nitrogen fixation by electric arc and catalyst |
| US4915915A (en) * | 1988-10-11 | 1990-04-10 | Treharne Richard W | Water-powdered piezoelectric unit for producing nitrogen fertilizer |
| US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
| US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| US5007419A (en) * | 1989-09-25 | 1991-04-16 | Allan Weinstein | Inhaler device |
| US5178138A (en) * | 1990-09-11 | 1993-01-12 | Walstrom Dennis R | Drug delivery device |
| US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| US5187305A (en) * | 1990-11-26 | 1993-02-16 | Glaxo Inc. | S-nitroso-N-alkonoylpenicillamines |
| US5396882A (en) * | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
| DK1516639T4 (en) * | 1990-12-05 | 2015-06-29 | Gen Hospital Corp | Use of NO to treat persistent pulmonary hypertension in newborns |
| IL101406A (en) * | 1991-03-29 | 1998-02-08 | Brigham & Womens Hospital | Pharmaceutical compositions containing s-nitrosothiol derivatives |
| US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
| AU3237193A (en) * | 1991-12-11 | 1993-07-19 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
-
1991
- 1991-12-05 DK DK04029366.4T patent/DK1516639T4/en active
- 1991-12-05 DE DE200812000012 patent/DE122008000012I2/de active Active
- 1991-12-05 DK DK92902708.4T patent/DK0560928T3/da active
- 1991-12-05 DE DE69127756T patent/DE69127756T2/de not_active Expired - Lifetime
- 1991-12-05 ES ES92902708T patent/ES2082732T3/es not_active Expired - Lifetime
- 1991-12-05 ES ES04029366.4T patent/ES2288660T5/es not_active Expired - Lifetime
- 1991-12-05 AU AU91498/91A patent/AU657726B2/en not_active Expired
- 1991-12-05 DE DE69133575T patent/DE69133575T2/de not_active Expired - Lifetime
- 1991-12-05 DE DE69133584A patent/DE69133584D1/de not_active Expired - Lifetime
- 1991-12-05 JP JP4502844A patent/JP2701978B2/ja not_active Expired - Lifetime
- 1991-12-05 ES ES97105021T patent/ES2132043T3/es not_active Expired - Lifetime
- 1991-12-05 DK DK97105021T patent/DK0786264T3/da active
- 1991-12-05 DE DE0560928T patent/DE560928T1/de active Pending
- 1991-12-05 EP EP07119550A patent/EP1875917A3/en not_active Withdrawn
- 1991-12-05 EP EP20040029366 patent/EP1516639B2/en not_active Expired - Lifetime
- 1991-12-05 EP EP97105021A patent/EP0786264B1/en not_active Revoked
- 1991-12-05 DE DE69133584T patent/DE69133584T4/de not_active Expired - Lifetime
- 1991-12-05 AT AT04029366T patent/ATE367842T2/de active
- 1991-12-05 DE DE122007000103C patent/DE122007000103I1/de active Pending
- 1991-12-05 AT AT92902708T patent/ATE158509T1/de active
- 1991-12-05 AT AT97105021T patent/ATE376850T1/de active
- 1991-12-05 CA CA002097823A patent/CA2097823C/en not_active Expired - Lifetime
- 1991-12-05 DE DE0786264T patent/DE786264T1/de active Pending
- 1991-12-05 DE DE2002199002 patent/DE10299002I1/de active Pending
- 1991-12-05 EP EP92902708A patent/EP0560928B1/en not_active Revoked
- 1991-12-05 SG SG1996002651A patent/SG47527A1/en unknown
- 1991-12-05 WO PCT/US1991/009111 patent/WO1992010228A1/en not_active Application Discontinuation
-
1994
- 1994-09-15 EE EE9400192A patent/EE03119B1/xx unknown
- 1994-12-09 US US08/353,508 patent/US5873359A/en not_active Expired - Lifetime
-
1995
- 1995-02-10 US US08/384,792 patent/US5485827A/en not_active Expired - Lifetime
-
1996
- 1996-06-30 GR GR960300032T patent/GR960300032T1/el unknown
-
1997
- 1997-02-20 JP JP03678597A patent/JP3510755B2/ja not_active Expired - Lifetime
- 1997-09-25 GR GR970402498T patent/GR3024865T3/el unknown
-
1998
- 1998-08-24 LV LVP-98-169A patent/LV12201B/en unknown
- 1998-09-24 HK HK98110945A patent/HK1010101A1/xx not_active IP Right Cessation
- 1998-09-24 HK HK99105833A patent/HK1020686A1/xx not_active IP Right Cessation
-
1999
- 1999-01-01 GR GR990300018T patent/GR990300018T1/el unknown
-
2002
- 2002-01-24 LU LU90886C patent/LU90886I2/xx unknown
- 2002-01-30 NL NL300081C patent/NL300081I2/nl unknown
- 2002-07-26 JP JP2002217936A patent/JP3718491B2/ja not_active Expired - Lifetime
-
2005
- 2005-09-22 HK HK05108350A patent/HK1076407A1/xx not_active IP Right Cessation
-
2007
- 2007-12-14 NL NL300327C patent/NL300327I2/nl unknown
- 2007-12-21 LU LU91404C patent/LU91404I2/fr unknown
-
2008
- 2008-04-01 NL NL300342C patent/NL300342I1/nl unknown
- 2008-04-30 LU LU91423C patent/LU91423I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU657726B2 (en) | Devices for treating pulmonary vasoconstriction and asthma | |
| CA2186892C (en) | Methods for treating pulmonary vasoconstriction and asthma | |
| US5823180A (en) | Methods for treating pulmonary vasoconstriction and asthma | |
| EP0692984B2 (en) | Systemic effects of nitric oxide inhalation | |
| Brilli et al. | Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension | |
| US6592848B1 (en) | Mixtures of oxygen and helium for the treatment of respiratory insufficiency | |
| AU2023219692A1 (en) | Treprostinil iloprost combination therapy | |
| JPS59500900A (ja) | 薬剤の送出装置 |